Clinical characteristics of MF patients studied
| Patient # . | Gender . | Age . | Diagnosis . | JAK2V617F allele burden (%)* . | CALR status* . | MPL mutation* . |
|---|---|---|---|---|---|---|
| SP9† | F | 58 | Post-PV MF | 43 | WT | WT |
| SP10 | F | 70 | Post-PV MF | 85 | WT | WT |
| SP14 | M | 79 | PMF | 2 | WT | WT |
| SP15 | M | 67 | PMF | 0 | Deletion | WT |
| SP16 | M | 66 | PMF | 0 | WT | WT |
| SP18 | F | 45 | Post-PV MF | 90 | WT | WT |
| SP19 | F | 64 | Post-PV MF | 78 | WT | WT |
| SP21 | M | 73 | PMF | 85 | WT | WT |
| SP22 | M | 76 | PMF | 25 | WT | WT |
| SP23 | F | 52 | ET-MF | 0 | Deletion | WT |
| SP24 | M | 51 | PMF | 28 | WT | N/A |
| PB13 | M | 64 | PMF | 0 | WT | WT |
| PB14 | M | 79 | PMF | 2 | WT | WT |
| PB16 | M | 66 | PMF | 0 | WT | WT |
| PB17 | M | 74 | PMF | 0 | WT | WT |
| PB18 | F | 45 | Post-PV MF | 90 | WT | WT |
| PB19 | F | 64 | Post-PV MF | 78 | WT | WT |
| PB153 | F | 56 | PMF | 0 | N/A | WT |
| PB158 | M | 74 | PMF | 76 | WT | WT |
| PB160 | F | 69 | PMF | 0 | N/A | N/A |
| PB177 | F | 71 | PMF | 50 | N/A | WT |
| PB180 | F | 59 | PMF | 0 | N/A | WT |
| PB185 | M | 72 | PMF | 0 | N/A | WT |
| PB186 | F | 49 | PMF | 0 | N/A | WT |
| PB190 | F | 56 | PMF | 0 | N/A | WT |
| PB195 | F | 75 | PMF | 47 | WT | N/A |
| Patient # . | Gender . | Age . | Diagnosis . | JAK2V617F allele burden (%)* . | CALR status* . | MPL mutation* . |
|---|---|---|---|---|---|---|
| SP9† | F | 58 | Post-PV MF | 43 | WT | WT |
| SP10 | F | 70 | Post-PV MF | 85 | WT | WT |
| SP14 | M | 79 | PMF | 2 | WT | WT |
| SP15 | M | 67 | PMF | 0 | Deletion | WT |
| SP16 | M | 66 | PMF | 0 | WT | WT |
| SP18 | F | 45 | Post-PV MF | 90 | WT | WT |
| SP19 | F | 64 | Post-PV MF | 78 | WT | WT |
| SP21 | M | 73 | PMF | 85 | WT | WT |
| SP22 | M | 76 | PMF | 25 | WT | WT |
| SP23 | F | 52 | ET-MF | 0 | Deletion | WT |
| SP24 | M | 51 | PMF | 28 | WT | N/A |
| PB13 | M | 64 | PMF | 0 | WT | WT |
| PB14 | M | 79 | PMF | 2 | WT | WT |
| PB16 | M | 66 | PMF | 0 | WT | WT |
| PB17 | M | 74 | PMF | 0 | WT | WT |
| PB18 | F | 45 | Post-PV MF | 90 | WT | WT |
| PB19 | F | 64 | Post-PV MF | 78 | WT | WT |
| PB153 | F | 56 | PMF | 0 | N/A | WT |
| PB158 | M | 74 | PMF | 76 | WT | WT |
| PB160 | F | 69 | PMF | 0 | N/A | N/A |
| PB177 | F | 71 | PMF | 50 | N/A | WT |
| PB180 | F | 59 | PMF | 0 | N/A | WT |
| PB185 | M | 72 | PMF | 0 | N/A | WT |
| PB186 | F | 49 | PMF | 0 | N/A | WT |
| PB190 | F | 56 | PMF | 0 | N/A | WT |
| PB195 | F | 75 | PMF | 47 | WT | N/A |
N/A, not available; WT, wild-type.
The JAK2V617F status of each MF patient was determined by analyzing PB granulocytes utilizing real-time allele-specific polymerase chain reaction (AS-PCR) assay. Mutational analysis of CALR was performed by sequencing regions of DNA, where known mutations in CALR have been previously described. MPLW515L/K mutations were detected by AS-PCR.
Spleen specimen from a patient with PMF or MF (SP); peripheral blood from a patient with PMF or MF (PB). SP14 and PB 14, SP16 and PB16, SP18 and PB18, SP19 and PB19 are each from the same patient.